Sign in
Taking peoplePhase 2

Upadacitinib for inflammatory muscle disease after stopping immunoglobulin infusions

Tests upadacitinib against placebo in adults with inflammatory muscle disease who stopped IVIG.

Key facts

Who runs it
Medical University Of Vienna
Where
Austria1 site in 1 countryChoose a country to see its sites
Registry title
IVIG-Spare Trial
Status
Recruiting
Phase
Phase 2
People taking part
10 people, planned
Started
23 Jan 2025
Planned end
31 May 2026
Type of study
Interventional
Record updated
30 October 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with idiopathic inflammatory myopathy (a muscle inflammation disease) who are stable on IVIG. It tests whether Upadacitinib 30 mg or placebo keeps the disease stable after IVIG is stopped.

Age
18 to 65 years in the criteria (the record's age field says 18 to 64 years)
Sex
All sexes
Disease stage
Idiopathic inflammatory myopathy, including PM, DM, IMNM, ASyS and OM. The disease must have been stable for at least 3 months.
Earlier treatment
People must have had IVIG at a stable dose and interval for at least 12 weeks before screening. They must also take a permitted background treatment (immunosuppressive drugs, antimalarials, or corticosteroids up to 10mg/day prednisone) at a stable dose for at least 12 weeks. People who had a JAK or TYK inhibitor before cannot join.

Main reasons for not taking part

  • Current or past hepatitis B or C, HIV infection, or tuberculosis
  • History of blood clots, heart attack, stroke or severe heart failure
  • History of cancer, or current smoking
  • Being pregnant or breastfeeding
  • Other conditions needing IVIG, such as immune deficiencies

The registry criteria, word for word

Show all 39 criteriaShow less

Who can take part

  • Written informed consent
  • Female and male subjects ≥ 18 and <=65 years of age at the time of signing the informed consent
  • Patients with clinical diagnosis of idiopathic inflammatory myopathies (IIM; including PM, DM, IMNM, ASyS, OM)
  • Receiving IVIG at stable dose and interval for at least 12 weeks before screening
  • Stable disease activity according to the discretion of the treating physician for at least 3 months
  • Receiving a permitted background treatment for IIM including immunosuppressive drugs or antimalarials, corticosteroids (up to 10mg/day prednisone äquivalent ) with stable dose and interval for at least 12 weeks before enrollment
  • Willing and being capable of understanding and following the study procedures
  • Female subjects agreeing to conduct efficient contraception, (unless they have no childbearing potential, means: o Women who are infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation o Women aged 55 years or older who are not on hormone therapy and who have had at least 6 months of spontaneous amenorrhea o Women aged 55 years or older who have a diagnosis of menopause o Women with amenorrhoe >12 months)

Who cannot take part

  • Conditions other than IIM requiring continuous or intermittent treatment with IVIG such as primary or secondary immune deficiencies
  • Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening
  • History of any malignancy prior to screening and patients with an increased risk of malignancy, which, according to the investigator, would pose an unacceptable risk to the patient if participating in the study
  • Previous treatment with a Janus kinase (JAK) inhibitor or tyrosine kinase (TYK) inhibitor (e.g. Baricitinib, Tofacitinib, Filgotinib, Deucravacitinib (an exception to this criterion may be granted for single dose exposure upon application to the sponsor on a case-by-case basis)
  • Female patients with reproductive potential not willing to use an effective method of contraception (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilisation) and are not willing to continue this precaution for the duration of the study until 6 months after receiving the last medication dose
  • Have a history of intravenous drug abuse, other illicit drug abuse, or chronic alcohol abuse within the 2 years prior to screening or are concurrently using, or expected to use during the study, illicit drugs (including marijuana)
  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following randomization
  • Past or current cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders, or any other serious and/or unstable illness that in the opinion of the investigator could constitute an unacceptable risk when taking investigational product or interfere with the interpretation of data
  • Plasmapheresis within 12 weeks prior to screening
  • Immunization with a live/attenuated vaccine within 12 weeks prior to baseline or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination at the discretion of the investigator); Patients currently smoking
  • Current or recent (< 4 weeks prior to randomization) clinically serious viral, bacterial, fungal or parasitic infection or any other active or recent infection, that in the opinion of the investigator would pose an unacceptable risk to the patient if participating in the study
  • Symptomatic herpes zoster infection within 12 weeks prior to randomization
  • Serologic evidence of current or past Hepatitis B, or Hepatitis C infection
  • Evidence of HIV infection and/or positive HIV antibodies
  • Other inflammatory rheumatic diseases (e.g. rheumatoid arthritis) that by discretion of investigator might interfere with conduction of the study
  • Positive QuantiFERON TB test, history of Tuberculosis, or active Tuberculosis-infection (without at least 4 weeks of adequate therapy for Tuberculosis and no history of re-exposure since their treatment was completed); patients must have no clinical features of active TB and have a screening chest x-ray with no evidence of active TB
  • Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
  • Any medical or psychological condition that in the opinion of the Principal Investigator would interfere with safe completion of the trial
  • Neuropathies or other conditions that might interfere with pain evaluation unless related to primary disease under investigation
  • Patients with known allergy or intolerance to the study drug or its’ excipients
  • History of venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism (PE); myocardial infarction, unstable ischemic heart disease stroke, or New York Heart Association Stage III/IV heart failure
  • History of recurrent (≥ 2) VTE (DVT/PE)
  • History of gastrointestinal organ perforation
  • Severe hepatic impairment
  • Symptomatic herpes simplex infection at the time of randomization
  • History of disseminated/complicated herpes zoster (for example, multidermatomal involvement, ophthalmic zoster, CNS involvement, or post-herpetic neuralgia)
  • Any of the following specific abnormalities on screening laboratory tests: a. ALT or AST >3 x ULN (if not explained by IIM disease activity) b. Alkaline phosphatase (ALP) >3 x ULN c. Total bilirubin ≥ 1.5 x ULN d. Hemoglobin <8 g/dL e. Total white blood cell count <2500 cells/µL (<2.50 x 103 / µL or <2.50 GI/L) f. Neutropenia (absolute neutrophil count [ANC] <1000 cells/ µL (<1.0 x 109/ L or <1.20 GI/L) g. Lymphopenia (lymphocyte count <500 cells/µL) (<0.5 x 109/L or <50GI/L) h. Thrombocytopenia (platelets <100,000 cells/µL) (<100 x 103/µL or <100 GI/L) i. eGFR <30 mL/min/1.73 m2 In the case of any of the aforementioned laboratory abnormalities, the test may be repeated once by the central laboratory during screening and values resulting from repeat testing may be accepted for enrolment eligibility if they meet the eligibility criterion
  • Are largely or wholly incapacitated permitting little or no self-care, such as being bedridden or confined to wheelchair
  • Pregnant women or nursing (breast feeding) mothers
  • Patients with lack of peripheral venous access
  • Screening electrocardiogram (ECG) abnormalities that, in the opinion of the investigator, are clinically significant and indicate an unacceptable risk for the patient´s participation in the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 64 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

To assess the proportion of patients in IVIG-free stable disease activity at week 16 after randomization across two study arms comparing Upadacitinib 30 mg vs Placebo.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
A randomized, double-blind, placebo-controlled Phase II proof of concept study evaluating efficacy and safety of Upadacitinib in patients with idiopathic inflammatory myopathies after withdrawal of intravenous immunoglobulins (IVIG) (IVIG-Spare)
Plain-language title
Upadacitinib for inflammatory muscle disease after stopping immunoglobulin infusionsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from 2024-513681-19-00, who can take part
Record updated
30 October 2024